Although the exact mechanisms are still unclear, several studies have described the activation of the MAPK/ERK1,2 pathway by ROS and the functional consequences in the pathogenesis of cardiovascular disorders such as ischemia, cardiac hypertrophy, cardiac remodelling after myocardial infarction, atherosclerosis, and vascular restenosis [6,10,12,30]. Here, MAPK3 is linked to cardiac hypertrophy.